nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A3—attention deficit hyperactivity disorder	0.346	0.431	CbGaD
Duloxetine—SLC6A4—attention deficit hyperactivity disorder	0.259	0.322	CbGaD
Duloxetine—HTR2A—attention deficit hyperactivity disorder	0.199	0.247	CbGaD
Duloxetine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0102	0.159	CbGeAlD
Duloxetine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.0061	0.0953	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00539	0.0843	CbGeAlD
Duloxetine—NPY1R—forebrain—attention deficit hyperactivity disorder	0.0037	0.0578	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00324	0.0506	CbGeAlD
Duloxetine—HTR6—forebrain—attention deficit hyperactivity disorder	0.00261	0.0407	CbGeAlD
Duloxetine—Naphazoline—ADRA2C—attention deficit hyperactivity disorder	0.00219	0.352	CrCbGaD
Duloxetine—NPY1R—nervous system—attention deficit hyperactivity disorder	0.00201	0.0314	CbGeAlD
Duloxetine—NPY1R—central nervous system—attention deficit hyperactivity disorder	0.00194	0.0302	CbGeAlD
Duloxetine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00156	0.0243	CbGeAlD
Duloxetine—NPY1R—brain—attention deficit hyperactivity disorder	0.00154	0.024	CbGeAlD
Duloxetine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00151	0.0235	CbGeAlD
Duloxetine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00143	0.0223	CbGeAlD
Duloxetine—HTR6—nervous system—attention deficit hyperactivity disorder	0.00141	0.0221	CbGeAlD
Duloxetine—HTR6—central nervous system—attention deficit hyperactivity disorder	0.00136	0.0213	CbGeAlD
Duloxetine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00126	0.0196	CbGeAlD
Duloxetine—HTR6—brain—attention deficit hyperactivity disorder	0.00108	0.0169	CbGeAlD
Duloxetine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.00103	0.0161	CbGeAlD
Duloxetine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000994	0.0155	CbGeAlD
Duloxetine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000943	0.0147	CbGeAlD
Duloxetine—Naphazoline—ADRA2A—attention deficit hyperactivity disorder	0.000936	0.15	CrCbGaD
Duloxetine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000846	0.0132	CbGeAlD
Duloxetine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000818	0.0128	CbGeAlD
Duloxetine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000814	0.0127	CbGeAlD
Duloxetine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000796	0.0124	CbGeAlD
Duloxetine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000787	0.0123	CbGeAlD
Duloxetine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000775	0.0121	CbGeAlD
Duloxetine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000755	0.0118	CbGeAlD
Duloxetine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000746	0.0117	CbGeAlD
Duloxetine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000688	0.0108	CbGeAlD
Duloxetine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000682	0.0107	CbGeAlD
Duloxetine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000657	0.0103	CbGeAlD
Duloxetine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000646	0.0101	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—attention deficit hyperactivity disorder	0.000643	0.103	CrCbGaD
Duloxetine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000639	0.00998	CbGeAlD
Duloxetine—HTR2C—brain—attention deficit hyperactivity disorder	0.000625	0.00976	CbGeAlD
Duloxetine—SLC6A4—brain—attention deficit hyperactivity disorder	0.000592	0.00926	CbGeAlD
Duloxetine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000522	0.00815	CbGeAlD
Duloxetine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000499	0.00779	CbGeAlD
Duloxetine—Fluoxetine—SLC6A4—attention deficit hyperactivity disorder	0.000439	0.0703	CrCbGaD
Duloxetine—Atomoxetine—HTR1B—attention deficit hyperactivity disorder	0.000417	0.0669	CrCbGaD
Duloxetine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.00041	0.00641	CbGeAlD
Duloxetine—Propranolol—HTR1B—attention deficit hyperactivity disorder	0.000396	0.0635	CrCbGaD
Duloxetine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000395	0.00617	CbGeAlD
Duloxetine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000386	0.00603	CbGeAlD
Duloxetine—Atomoxetine—SLC6A3—attention deficit hyperactivity disorder	0.000377	0.0604	CrCbGaD
Duloxetine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000374	0.00584	CbGeAlD
Duloxetine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00036	0.00562	CbGeAlD
Duloxetine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000352	0.00549	CbGeAlD
Duloxetine—Fluoxetine—HTR2A—attention deficit hyperactivity disorder	0.000337	0.0541	CrCbGaD
Duloxetine—HTR2A—brain—attention deficit hyperactivity disorder	0.000313	0.0049	CbGeAlD
Duloxetine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000286	0.00446	CbGeAlD
Duloxetine—Atomoxetine—SLC6A4—attention deficit hyperactivity disorder	0.000282	0.0452	CrCbGaD
Duloxetine—Atomoxetine—HTR2A—attention deficit hyperactivity disorder	0.000217	0.0347	CrCbGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00016	0.00128	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000157	0.00126	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000157	0.00125	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000157	0.00125	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000156	0.00125	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000156	0.00125	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000156	0.00125	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000154	0.00123	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000154	0.00123	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000153	0.00123	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000153	0.00123	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000153	0.00122	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000153	0.00122	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000151	0.00121	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000151	0.00121	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00015	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000148	0.00119	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000146	0.00117	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000146	0.00117	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000146	0.00116	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000141	0.00113	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000141	0.00113	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000141	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00014	0.00112	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000139	0.00111	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000138	0.0011	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000137	0.0011	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000137	0.0011	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000134	0.00107	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000132	0.00105	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000131	0.00105	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00013	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00013	0.00104	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000129	0.00103	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000128	0.00102	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000127	0.00102	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000127	0.00101	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000125	0.001	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000122	0.000979	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000122	0.000973	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000121	0.000968	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000121	0.000966	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00012	0.000961	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00012	0.000956	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000119	0.000954	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000119	0.000948	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000118	0.000944	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000116	0.000927	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000115	0.000918	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000113	0.000903	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000113	0.000903	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000112	0.000894	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000111	0.000891	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000111	0.000886	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000109	0.000874	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000108	0.000868	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.00086	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000107	0.000858	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000106	0.000849	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000105	0.000843	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000105	0.00084	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000104	0.00083	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000103	0.000823	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000103	0.00082	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000102	0.000813	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000102	0.000812	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000101	0.00081	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.99e-05	0.0008	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	9.97e-05	0.000797	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.87e-05	0.00079	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.87e-05	0.00079	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.87e-05	0.000789	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.83e-05	0.000787	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	9.8e-05	0.000784	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.76e-05	0.000781	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	9.68e-05	0.000774	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.67e-05	0.000773	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.57e-05	0.000765	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.55e-05	0.000764	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.51e-05	0.000761	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	9.48e-05	0.000759	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	9.4e-05	0.000752	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	9.31e-05	0.000745	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.28e-05	0.000743	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	9.27e-05	0.000742	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	9.26e-05	0.000741	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	9.21e-05	0.000736	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	9.2e-05	0.000736	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	9.01e-05	0.000721	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.96e-05	0.000717	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.89e-05	0.000711	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	8.82e-05	0.000705	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.63e-05	0.00069	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.6e-05	0.000688	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	8.54e-05	0.000683	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.46e-05	0.000677	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	8.41e-05	0.000673	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	8.39e-05	0.000671	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.36e-05	0.000669	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.32e-05	0.000665	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	8.31e-05	0.000665	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	8.29e-05	0.000663	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	8.26e-05	0.000661	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.21e-05	0.000657	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.11e-05	0.000649	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.92e-05	0.000633	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.76e-05	0.000621	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.73e-05	0.000619	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	7.72e-05	0.000618	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.56e-05	0.000605	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.49e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.36e-05	0.000589	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.3e-05	0.000584	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.27e-05	0.000582	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.27e-05	0.000582	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.22e-05	0.000578	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.19e-05	0.000575	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.04e-05	0.000564	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.88e-05	0.00055	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	6.78e-05	0.000543	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.77e-05	0.000542	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.74e-05	0.000539	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.71e-05	0.000537	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.71e-05	0.000537	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	6.67e-05	0.000534	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	6.67e-05	0.000534	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.63e-05	0.00053	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	6.62e-05	0.000529	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.5e-05	0.00052	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.44e-05	0.000515	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.39e-05	0.000512	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.39e-05	0.000511	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.38e-05	0.000511	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.35e-05	0.000508	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.33e-05	0.000507	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.31e-05	0.000505	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.31e-05	0.000505	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.24e-05	0.0005	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.23e-05	0.000498	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.12e-05	0.000489	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.93e-05	0.000475	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.88e-05	0.00047	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.8e-05	0.000464	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.77e-05	0.000461	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.75e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.65e-05	0.000452	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.65e-05	0.000452	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.58e-05	0.000446	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.54e-05	0.000443	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.5e-05	0.00044	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.42e-05	0.000433	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.39e-05	0.000431	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.38e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.38e-05	0.00043	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.34e-05	0.000427	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.29e-05	0.000423	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.22e-05	0.000417	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.2e-05	0.000416	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.13e-05	0.00041	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.07e-05	0.000405	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	5e-05	0.0004	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.94e-05	0.000396	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.88e-05	0.000391	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.74e-05	0.000379	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.72e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.7e-05	0.000376	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.67e-05	0.000374	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.37e-05	0.00035	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.29e-05	0.000343	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.27e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.25e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.24e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.23e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.16e-05	0.000333	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.16e-05	0.000333	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.11e-05	0.000329	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.08e-05	0.000327	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.08e-05	0.000326	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.97e-05	0.000317	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.92e-05	0.000313	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.84e-05	0.000307	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.83e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.79e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.78e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.73e-05	0.000298	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.71e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.69e-05	0.000295	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.67e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.64e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.61e-05	0.000289	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.61e-05	0.000289	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.57e-05	0.000285	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.54e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.48e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.45e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.42e-05	0.000274	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.34e-05	0.000267	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.32e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.31e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.28e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.24e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.18e-05	0.000255	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.08e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.03e-05	0.000242	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.02e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.99e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.88e-05	0.000231	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.8e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.79e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.68e-05	0.000214	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.62e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.52e-05	0.000202	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.5e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.43e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.34e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.27e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.23e-05	0.000179	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.22e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.2e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.19e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.05e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.04e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.97e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.95e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.94e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.91e-05	0.000153	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.81e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.81e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.78e-05	0.000143	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.78e-05	0.000142	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.65e-05	0.000132	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.53e-05	0.000122	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.53e-05	0.000122	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.5e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.44e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.44e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.4e-05	0.000112	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.37e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.22e-05	9.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.16e-05	9.31e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.09e-05	8.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.09e-05	8.69e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.03e-05	8.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	9.26e-06	7.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	9.2e-06	7.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.92e-06	7.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.62e-06	6.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.61e-06	5.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	4.69e-06	3.75e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	3.97e-06	3.18e-05	CbGpPWpGaD
